

ACTIVAERO AND ERASMUS MC ANNOUNCE RESEARCH COLLABORATION

Gemünden/Germany and Rotterdam/Netherlands, April 23, 2007 – German based aerosol device specialist Activaero GmbH and Erasmus Medisch Centrum in Rotterdam today announced a research collaboration for advanced lung targeting of inhaled aerosols. Within this collaboration, Erasmus MC will conduct several clinical trials in the field of different lung diseases. Activaero will support Erasmus MC with aerosol consulting and by the supply of AKITA² inhalation devices, including the APIXNEB™ nebuliser handset developed and supplied by PARI Pharma GmbH.

The department of Paediatric Pulmonology and Allergology at Erasmus MC specializes in research of lung diseases such as cystic fibrosis and asthma. Steady inflammation and infections of the lung cause the deterioration of the patient's lung function and the general progression of the disease. Clinical data suggest that inflammation and infections start within the small airways of the lung.

“In our opinion, there is a strong rationale that for certain diseases more inhaled drug should reach the small airways in order to provide efficient control of the disease,” comments Ass. Prof. Dr. Harm Tiddens, Head of the Erasmus MC CF-team. He continues: “The efficiency of aerosol delivery to the small airways with conventional devices, however, has been limited due to the lack of control of the patient's breathing during the inhalation treatment. Activaero's AKITA technology now provides for improved drug targeting into the relevant region of the lungs.”

Dr. Gerhard Scheuch, CEO of Activaero, added: “We are very proud of the collaboration with Erasmus MC, since we know them as experts in the pulmonary field. We all hope that our technology helps to improve the inhalation therapy for patients with lung diseases.”

About Erasmus Medisch Centrum

Erasmus MC, established in the city of Rotterdam, is a university medical center in which (new) knowledge is both being generated and passed on to (future) professionals. This knowledge covers a broad field, ranging from illness to health and from individual to community healthcare. The knowledge generated and new findings will benefit daily care and treatment of patients.

About Activaero

Activaero is a drug delivery company, specializing in highly efficient aerosol technology and inhalation systems. Activaero partners globally with leading pharmaceutical and biotechnology companies to apply its inhalation platforms to pharmaceuticals that require critical dosage control. Activaero is privately held and has facilities in Germany (Munich and Gemünden/Wohra) and in the USA (Dublin, Ohio).

Contacts

*Activaero GmbH
Axel Fischer
Wohraer Str. 37
35285 Gemünden
Germany*

*Phone: +49 (6453) 64818 – 0
Fax: +49 (6453) 64818 – 22
E-Mail: fischer@activaero.de*

*Erasmus Medical Center Rotterdam
Department of Paediatrics Sophia Children's
Hospital
Ass. Prof. Dr. Harm A.W.M. Tiddens
P.O. Box 2060
3000 CB Rotterdam
The Netherlands*

*Phone: +31 (10) 463 – 6263
Fax: +31 (10) 463 – 6811
E-Mail: h.tiddens@erasmusmc.nl*

The APIXNEB™ Nebulizer is developed and supplied by PARI Pharma GmbH. APIXNEB™ is a trademark of Activaero GmbH.